NCT01412281View on ClinicalTrials.gov

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers

PHASE3CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Virosomal influenza vaccine (AdImmune HA Antigen)

Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus

BIOLOGICAL

Virosomal influenza vaccine (CSL HA Antigen)

Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus

Trial Locations (1)

4123

Covance Clinical Research Unit AG, Allschwil

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT01412281 - Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers | Biotech Hunter | Biotech Hunter